Follow
Jonathan Fintzi
Jonathan Fintzi
National Institute of Allergy and Infectious Diseases
Verified email at nih.gov
Title
Cited by
Cited by
Year
An immune-based biomarker signature is associated with mortality in COVID-19 patients
MS Abers, OM Delmonte, EE Ricotta, J Fintzi, DL Fink, AAA de Jesus, ...
JCI insight 6 (1), 2021
3202021
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
KS Corbett, MC Nason, B Flach, M Gagne, S O’Connell, TS Johnston, ...
Science 373 (6561), eabj0299, 2021
2342021
Ambient air quality measurements from a continuously moving mobile platform: Estimation of area-wide, fuel-based, mobile source emission factors using absolute principal …
T Larson, T Gould, EA Riley, E Austin, J Fintzi, L Sheppard, M Yost, ...
Atmospheric Environment 152, 201-211, 2017
582017
Multi-pollutant mobile platform measurements of air pollutants adjacent to a major roadway
EA Riley, L Banks, J Fintzi, TR Gould, K Hartin, LN Schaal, M Davey, ...
Atmospheric Environment 98, 492-499, 2014
462014
Immune correlates of protection by mRNA-1273 immunization against SARS-CoV-2 infection in nonhuman primates
KS Corbett, MC Nason, B Flach, M Gagne, S O’Connell, TS Johnston, ...
BioRxiv, 2021.04. 20.440647, 2021
442021
Efficient data augmentation for fitting stochastic epidemic models to prevalence data
J Fintzi, X Cui, J Wakefield, VN Minin
Journal of Computational and Graphical Statistics 26 (4), 918-929, 2017
392017
Discovering disease-causing pathogens in resource-scarce Southeast Asia using a global metagenomic pathogen monitoring system
JA Bohl, S Lay, S Chea, V Ahyong, DM Parker, S Gallagher, J Fintzi, ...
Proceedings of the National Academy of Sciences 119 (11), e2115285119, 2022
292022
Asthma is associated with increased risk of intubation but not hospitalization or death in coronavirus disease 2019
JA Rosenthal, SF Awan, J Fintzi, A Keswani, D Ein
Annals of Allergy, Asthma & Immunology 126 (1), 93, 2021
292021
Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity
CM Long, PA Beare, DC Cockrell, J Fintzi, M Tesfamariam, CI Shaia, ...
npj Vaccines 6 (1), 38, 2021
262021
Comparison of the transmission efficiency and plague progression dynamics associated with two mechanisms by which fleas transmit Yersinia pestis
CF Bosio, CO Jarrett, DP Scott, J Fintzi, BJ Hinnebusch
PLoS pathogens 16 (12), e1009092, 2020
192020
A linear noise approximation for stochastic epidemic models fit to partially observed incidence counts
J Fintzi, J Wakefield, VN Minin
Biometrics 78 (4), 1530-1541, 2022
182022
A deferred-vaccination design to assess durability of COVID-19 vaccine effect after the placebo group is vaccinated
D Follmann, J Fintzi, MP Fay, HE Janes, LR Baden, HM El Sahly, ...
Annals of internal medicine 174 (8), 1118-1125, 2021
162021
Assessing vaccine durability in randomized trials following placebo crossover
J Fintzi, D Follmann
Statistics in Medicine 40 (27), 5983-6007, 2021
122021
Mycobacterial testing trends, United States, 2009–2015
SG Dean, EE Ricotta, J Fintzi, YL Lai, SS Kadri, KN Olivier, A Zelazny, ...
Emerging infectious diseases 26 (9), 2243, 2020
122020
Deconstructing the treatment effect of remdesivir in the adaptive coronavirus disease 2019 (COVID-19) treatment trial-1: implications for critical care resource utilization
J Fintzi, T Bonnett, DA Sweeney, NA Huprikar, A Ganesan, MG Frank, ...
Clinical Infectious Diseases 74 (12), 2209-2217, 2022
112022
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 373: eabj0299
KS Corbett, MC Nason, B Flach, M Gagne, S O’Connell, TS Johnston, ...
112021
Assessing durability of vaccine effect following blinded crossover in COVID-19 vaccine efficacy trials
D Follmann, J Fintzi, MP Fay, HE Janes, L Baden, H El Sahly, TR Fleming, ...
medRxiv, 2020
112020
Using multiple data streams to estimate and forecast SARS-CoV-2 transmission dynamics, with application to the virus spread in Orange County, California.
J Fintzi, D Bayer, I Goldstein, K Lumbard, E Ricotta, S Warner, LM Busch, ...
Arxiv, arXiv: 2009.02654 v1-arXiv: 2009.02654 v1, 2020
82020
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
D Follmann, MP O’Brien, J Fintzi, MP Fay, D Montefiori, A Mateja, ...
Nature Communications 14 (1), 3605, 2023
72023
Deconstructing the treatment effect of remdesivir in the Adaptive COVID-19 Treatment Trial-1: implications for critical care resource utilization
J Fintzi, T Bonnett, DA Sweeney, NA Huprikar, A Ganesan, MG Frank, ...
Clin Infect Dis 74, 2209-17, 2021
62021
The system can't perform the operation now. Try again later.
Articles 1–20